- Home
- AMBC vs OMER Comparison
AMBC vs OMER Comparison
Compare AMBC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- OMER
- Stock Information
- Founded
- AMBC 1991
- OMER 1994
- Country
- AMBC United States
- OMER United States
- Employees
- AMBC N/A
- OMER N/A
- Industry
- AMBC Property-Casualty Insurers
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- AMBC Finance
- OMER Health Care
- Exchange
- AMBC Nasdaq
- OMER Nasdaq
- Market Cap
- AMBC 543.0M
- OMER 530.2M
- IPO Year
- AMBC 1991
- OMER 2009
- Fundamental
- Price
- AMBC $11.51
- OMER $9.13
- Analyst Decision
- AMBC Strong Buy
- OMER Buy
- Analyst Count
- AMBC 2
- OMER 4
- Target Price
- AMBC $17.00
- OMER $22.50
- AVG Volume (30 Days)
- AMBC 431.2K
- OMER 509.4K
- Earning Date
- AMBC 02-25-2025
- OMER 03-31-2025
- Dividend Yield
- AMBC N/A
- OMER N/A
- EPS Growth
- AMBC N/A
- OMER N/A
- EPS
- AMBC N/A
- OMER N/A
- Revenue
- AMBC $398,000,000.00
- OMER N/A
- Revenue This Year
- AMBC N/A
- OMER N/A
- Revenue Next Year
- AMBC N/A
- OMER N/A
- P/E Ratio
- AMBC N/A
- OMER N/A
- Revenue Growth
- AMBC 22.46
- OMER N/A
- 52 Week Low
- AMBC $10.12
- OMER $2.61
- 52 Week High
- AMBC $18.45
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- AMBC 45.24
- OMER 50.45
- Support Level
- AMBC $11.35
- OMER $8.28
- Resistance Level
- AMBC $11.72
- OMER $9.08
- Average True Range (ATR)
- AMBC 0.31
- OMER 0.58
- MACD
- AMBC 0.05
- OMER -0.05
- Stochastic Oscillator
- AMBC 59.15
- OMER 62.58
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. The business operations of the company include Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. The Company has three reportable segments namely Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. Majority of revenues are earned from Legacy Financial Guarantee Insurance segment.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.